At a Glance
- Company: Banyan BioInnovations
- Location: Boston, US
- Funding: More than $100 million
- Partner: ICON plc
- Focus area: Clinical-stage NewCos and drug development services
What happened?
Banyan BioInnovations launched as a new investment firm with more than $100 million in initial commitments from life science investors. The company will create and finance “NewCos” around promising clinical-stage assets, while also providing development support to help move them through clinical and regulatory milestones.
Why does it matter?
The model is meant to fill the funding gap that often leaves clinical-stage assets stranded between early promise and late-stage proof. By combining capital with hands-on operating support, Banyan is trying to lower development risk and make promising drugs more attractive to investors and originators.
Who’s behind it?
Banyan is an offshoot of Locust Walk, the life sciences investment bank, and is led by Geoff Meyerson and Barbara White. ICON is both a strategic collaborator and an equity investor, giving Banyan direct access to CRO infrastructure for trial execution.
How was it achieved?
Banyan’s approach combines asset sourcing, due diligence, clinical strategy, operations, regulatory support and CMC services under one umbrella. The company says each NewCo will be built with broad initial capitalisation and a clear path to value creation from launch.
What’s next?
Banyan will start assembling its first portfolio of NewCos using its global sourcing network across the US, Asia and Europe. The company aims to use ICON’s clinical execution capabilities to accelerate trials and improve the odds of success for the assets it selects.
What are people saying?
Geoff Meyerson said the model creates a “repeatable operating system” that aligns originators, investors and operators around a shared goal. Barbara White said the combination of strategy, execution and quality is essential to bringing promising therapies to patients.